Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dendritic cell-based immunotherapy.
Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK. Osada T, et al. Among authors: clay tm. Int Rev Immunol. 2006 Sep-Dec;25(5-6):377-413. doi: 10.1080/08830180600992456. Int Rev Immunol. 2006. PMID: 17169781 Review.
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, Diniz MA, Spector N, Clay TM, Chen W, Morse MA, Lyerly HK. Osada T, et al. Among authors: clay tm. Breast Cancer Res. 2018 Aug 9;20(1):90. doi: 10.1186/s13058-018-1023-x. Breast Cancer Res. 2018. PMID: 30092835 Free PMC article.
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM. Morse MA, et al. Among authors: clay tm. Int J Cancer. 2010 Jun 15;126(12):2893-903. doi: 10.1002/ijc.24995. Int J Cancer. 2010. PMID: 19856307 Free PMC article.
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.
Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, Morse MA, Lyerly HK, Clay TM. Hartman ZC, et al. Among authors: clay tm. Clin Cancer Res. 2010 Mar 1;16(5):1466-77. doi: 10.1158/1078-0432.CCR-09-2549. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179231 Free PMC article.
118 results